Sebastian Ferri, Carlo Montagna, Marta Casini, Luca Malvezzi, Francesca Pirola, Elena Russo, Francesca Racca, Maria Rita Messina, Francesca Puggioni, Emanuele Nappi, Giovanni Costanzo, Lorenzo Del Moro, Giuseppe Mercante, Giuseppe Spriano, Giorgio Walter Canonica, Giovanni Paoletti, Enrico Heffler
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant burden on patients' quality of life and impaired sleep quality. The most common CRSwNP endotype is characterized by type-2 inflammation, with enhanced production of interleukin (IL)-4, IL-5 and IL-13. Dupilumab is a monoclonal antibody against IL-4 receptor-alpha, which inhibits both IL-4 and IL-13 signaling, and was recently approved for treatment of CRSwNP. OBJECTIVE: We investigated the effect of Dupilumab on sleep quality in patients with CRSwNP in a real-life setting...
August 29, 2023: Annals of Allergy, Asthma & Immunology